keyword
MENU ▼
Read by QxMD icon Read
search

Entecavir

keyword
https://www.readbyqxmd.com/read/28230928/reactivation-of-hepatitis-b-in-patients-of-chronic-hepatitis-c-with-hepatitis-b-virus-infection-treated-with-direct-acting-antivirals
#1
Ming-Lun Yeh, Chung-Feng Huang, Meng-Hsuan Hsieh, Yu-Min Ko, Kuan-Yu Chen, Ta-Wei Liu, Yi-Hung Lin, Po-Cheng Liang, Ming-Yen Hsieh, Zu-Yau Lin, Shinn-Cherng Chen, Ching-I Huang, Jee-Fu Huang, Po-Lin Kuo, Chia-Yen Dai, Ming-Lung Yu, Wan-Long Chuang
BACKGROUND AND AIMS: Hepatitis B virus (HBV) may reactivate when treating chronic hepatitis C (CHC) with direct acting antivirals (DAA). We aim to investigate the risk of HBV reactivation during DAA therapy. METHODS: CHC patients receiving pan-oral DAA therapy from Dec. 2013 to Aug. 2016 were evaluated. Fifty-seven patients that had a past HBV infection (negative hepatitis B surface antigen (HBsAg)) and positive hepatitis B core antibody (Anti-HBc)) and 7 patients that had a current HBV infection (positive HBsAg) were enrolled...
February 23, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28220833/early-hepatitis-b-surface-antigen-decline-predicts-treatment-response-to-entecavir-in-patients-with-chronic-hepatitis-b
#2
Cheng-Yuan Peng, Hsueh-Chou Lai, Wen-Pang Su, Chia-Hsin Lin, Po-Heng Chuang, Sheng-Hung Chen, Ching-Hsiang Chen
Early declines in serum hepatitis B surface (HBsAg) levels, their optimal cutoffs, and association with therapeutic endpoints in chronic hepatitis B (CHB) patients receiving entecavir treatment remain unclear. We prospectively enrolled 529 patients (195 hepatitis B e antigen [HBeAg]-positive and 334 HBeAg-negative) with a median treatment duration of 49.2 months. Median HBsAg levels declined significantly in both groups at Month 3, but only at Months 6-12 in the HBeAg-negative group. Both groups exhibited a significant HBsAg decline with each successive year of treatment...
February 21, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28218868/-diagnosis-and-treatment-of-chronic-hepatitis-b-and-d-national-consensus-guideline-in-hungary-from-15-october-2016
#3
Gábor Horváth, Zsuzsanna Gerlei, Judit Gervain, Gabriella Lengyel, Mihály Makara, Alajos Pár, László Rókusz, Ferenc Szalay, István Tornai, Klára Werling, Béla Hunyady
Diagnosis and treatment of HBV/HDV infection means for the patient to be able to maintain working capacity, to increase quality of life, to prevent cancer, and to prolong life expectancy, while society benefits from eliminating the chances of further transmission of the viruses, and decreasing the overall costs of serious complications. The guideline delineates the treatment algorithms for 2017 set by a consensus meeting of physicians involved in the treatment of these diseases. The prevalence of HBV infection in the Hungarian general population is 0...
February 2017: Orvosi Hetilap
https://www.readbyqxmd.com/read/28208002/expression-of-hepatocyte-hepatitis-b-core-antigen-and-hepatitis-b-surface-antigen-as-a-marker-in-the-management-of-chronic-hepatitis-b-patients
#4
Sun Young Yim, Tae Hyung Kim, Suh Sang Jun, Eun Sun Kim, Bora Keum, Yeon Seok Seo, Hyung Joon Yim, Yoon Tae Jeen, Hoon Jai Chun, Hong Sik Lee, Soon Ho Um, Chang Duck Kim, Nam Hee Won, Ho Sang Ryu
Background/Aims: We aimed to clarify the association of HBsAg/HBcAg with the disease status and treatment response in patients with chronic hepatitis B (CHB). Methods: We investigated 171 biopsy-proven entecavir-treated CHB patients (109 HBeAg-positive, 62 HBeAg-negative). HBcAg expression was positive when ≥10% of hepatocytes stained, and classified into nuclear, mixed, and cytoplasmic patterns. HBsAg expressions were intracytoplasmic (diffuse, globular, and submembranous) and membranous...
February 17, 2017: Gut and Liver
https://www.readbyqxmd.com/read/28197805/economic-analysis-and-budget-impact-of-tenofovir-and-entecavir-in-the-first-line-treatment-of-hepatitis-b-virus-in-italy
#5
M Ruggeri, M Basile, S Coretti, C Drago, A Cicchetti
BACKGROUND: Chronic hepatitis B is a common, progressive disease, particularly when viral replication is detected. Oral antivirals can suppress viral replication and prevent or delay the development of cirrhosis and liver-related complications. The treatments of chronic hepatitis B cannot totally cure the disease but can prevent its progression to hepatocellular carcinoma, decreasing the levels of both morbidity and mortality. To date, there are several therapies indicated by the international guidelines as first-line treatments for the management of hepatitis B; two of the most effective are those based on either tenofovir or entecavir...
February 14, 2017: Applied Health Economics and Health Policy
https://www.readbyqxmd.com/read/28192212/anti-hbv-drugs-suppress-the-growth-of-hbv-related-hepatoma-cells-via-down-regulation-of-hepatitis-b-virus-x-protein
#6
Shuqin Zhang, Shan Gao, Man Zhao, Yunxia Liu, Yanan Bu, Qiulei Jiang, Qiang Zhao, Lihong Ye, Xiaodong Zhang
Chronic infection of hepatitis B virus (HBV) is closely associated with the development of hepatocellular carcinoma (HCC). Meta-analyses show that adjuvant anti-HBV therapy is effective for HBV-related HCC patients in clinical. However, the significance that anti-HBV drugs depress HCC is poorly understood. Here, we investigated the effects of telbivudine (LdT), entecavir (ETV) and interferon-α2b (IFN-α2b) on HBV-related HCC. Our data showed that the treatment with the drugs significantly suppressed the growth of HBV-expressing hepatoma cells in vitro and in vivo, but failed to work in HBV-free liver cells...
February 9, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28183162/management-of-antiviral-resistance-in-chronic-hepatitis-b
#7
REVIEW
Young-Suk Lim
The primary goal of therapy for chronic hepatitis B (CHB) is to prevent liver disease progression. Hepatitis B surface antigen (HBsAg) seroclearance or seroconversion is regarded as an optimal endpoint to discontinue treatment. However, HBsAg seroclearance occurs very rarely with nucleos(t)ide analog (NUC) treatment, and long-term, almost indefinite, NUC treatment is required for the majority of patients. In patients with drug-resistant hepatitis B virus (HBV), a combination of tenofovir disoproxil fumarate (TDF) and entecavir (ETV), which is currently regarded as the strongest combination therapy against HBV, would be potentially safe to prevent the emergence of additional HBV resistance mutations...
February 13, 2017: Gut and Liver
https://www.readbyqxmd.com/read/28165543/effect-of-nucleoside-analogues-in-the-treatment-of-hepatitis-b-cirrhosis-and-its-effect-on-th17-cell
#8
J Zhang, H Ying, L Wei, L-J Hong
OBJECTIVE: We conducted this study to analyze the effects of nucleoside analogues in the treatment of hepatitis B cirrhosis and its effect on Th17 cells. PATIENTS AND METHODS: 120 patients were randomly divided into lamivudine combined with adefovir dipivoxil group (combined group) and entecavir group. There were 59 cases in the combined group and 59 cases in entecavir group. The combined group was administered lamivudine 100 mg/d + adefovir dipivoxil 10 mg/d and entecavir group was administered entecavir 0...
January 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/28157182/efficient-genome-replication-of-hepatitis-b-virus-using-adenovirus-vector-a-compact-pregenomic-rna-expression-unit
#9
Mariko Suzuki, Saki Kondo, Manabu Yamasaki, Norie Matsuda, Akio Nomoto, Tetsuro Suzuki, Izumu Saito, Yumi Kanegae
The complicated replication mechanisms of hepatitis B virus (HBV) have impeded HBV studies and anti-HBV therapy development as well. Herein we report efficient genome replication of HBV applying adenovirus vectors (AdVs) showing high transduction efficiency. Even in primary hepatocytes derived from humanized mice the transduction efficiencies using AdVs were 450-fold higher compared than those using plasmids. By using an expression unit consisting of the CMV promoter, 1.03-copy HBV genome and foreign poly(A) signal, we successfully generated an improved AdV (HBV103-AdV) that efficiently provided 58 times more pregenomic RNA than previously reported AdVs...
February 3, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28141486/usefulness-of-humanized-cdna-upa-scid-mice-for-the-study-of-hepatitis-b-virus-and-hepatitis-c-virus-virology
#10
Takuro Uchida, Michio Imamura, Hiromi Kan, Nobuhiko Hiraga, C Nelson Hayes, Masataka Tsuge, Hiromi Abe-Chayama, Hiroshi Aikata, Grace Naswa Makokha, Daiki Miki, Hidenori Ochi, Yuji Ishida, Chise Tateno, Kazuaki Chayama
Urokinase-type plasminogen activator-severe combined immunodeficiency (uPA/SCID) mice transplanted with human hepatocytes are permissive for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. However, one of the problems affecting uPA transgenic mice is the expansion of mouse hepatocyte colonies due to homologous recombination of the uPA gene. In this study, we attempted to infect HBV and HCV in humanized cDNA-uPA/SCID mice, a novel uPA transgenic mouse model designed to overcome this disadvantage...
January 28, 2017: Journal of General Virology
https://www.readbyqxmd.com/read/28140702/antiviral-therapies-for-managing-viral-hepatitis-in-lymphoma-patients
#11
Michele Merli, Sara Rattotti, Manuel Gotti, Luca Arcaini
In patients with lymphoma the detection of positive hepatitis B or C viruses (HBV and HCV) serology involves crucial therapeutic consequences. In HBV-infected patients the serological profile of active (HBsAg-positive) or resolved (HBsAg-negative/anti-HBcAb-positive) infection is associated to differential risk of viral reactivation during rituximab-based therapy and require appropriate strategies of monitoring and of antiviral prophylaxis. In HCV-associated NHL patients consolidated data demonstrated that interferon (IFN)-based antiviral therapy (AT) is able to induce lymphoma regression strictly related to viral eradication, while preliminary data of the new direct-acting antivirals (DAAs) are very promising...
January 31, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28139541/comparative-evaluation-of-long-term-monotherapies-combination-therapies-in-patients-with-chronic-hepatitis-b-a-pilot-study
#12
Manjita Srivastava, Neha Singh, Vinod Kumar Dixit, Gopal Nath, Ashok Kumar Jain
BACKGROUND & OBJECTIVES: Reduction of viraemia in patients with chronic hepatitis B virus (HBV) infection using nucleoside/nucleotide analogues reduces fatal liver disease-related events, but development of resistance in virus presents serious clinical challenge. Therefore, comparative evaluation of prolonged antiviral monotherapy and combination therapies was prospectively studied to assess their influence on viral suppression, rapidity of response, development of drug resistance and surfacing mutants in chronic liver disease (CLD) patients...
September 2016: Indian Journal of Medical Research
https://www.readbyqxmd.com/read/28137301/comparison-of-telbivudine-and-entecavir-on-the-change-of-off-treatment-egfr-after-3%C3%A2-years-of-treatment-in-non-cirrhotic-chronic-hepatitis-b-patients
#13
COMPARATIVE STUDY
Yang-Sheng Lin, Shou-Chuan Shih, Horng-Yuan Wang, Ching-Chung Lin, Chen-Wang Chang, Ming-Jen Chen
BACKGROUND: The change of estimated glomerular filtration rate (eGFR) with off-treatment nucleos(t)ide analogues (NA) in chronic hepatitis B patients (CHB) is unclear. This study is aimed to evaluate the off-treatment eGFR after 3 years of therapy with telbivudine (LdT) or entecavir (ETV) and to assess predictive factors for eGFR improvement. METHODS: From January 2009 to December 2011, we identified NA-naïve patients who were at least 20 years of age diagnosed with compensated CHB...
January 31, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/28130815/hepatitis-b-surface-antigen-loss-and-clinical-outcomes-between-hbeag-negative-cirrhosis-patients-who-discontinued-or-continued-nucleoside-analog-therapy
#14
Chao-Hung Hung, Jing-Hung Wang, Sheng-Nan Lu, Tsung-Hui Hu, Chung-Mo Lee, Chien-Hung Chen
We investigated the incidence and predictors of post-treatment hepatitis B virus (HBV) relapse and hepatitis B surface antigen (HBsAg) loss. The rates of HBsAg loss and hepatocellular carcinoma (HCC) development in HBeAg-negative patients with cirrhosis who continued nucleoside analog (NA) treatment were compared with those who discontinued treatment. Compensated cirrhotic patients who had discontinued NA treatment for at least 12 months (discontinuing group; n=73) and patients who continued entecavir treatment for at least 4 years (continuing group; n=158) were recruited...
January 27, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28122151/serum-viral-load-at-the-virological-relapse-predicts-subsequent-clinical-flares-in-chronic-hepatitis-b-patients-off-entecavir-therapy
#15
Yao-Chun Hsu, Lein-Ray Mo, Chi-Yang Chang, Ming-Shiang Wu, Tzeng-Huey Yang, Jia-Horng Kao, Chieh-Chang Chen, Cheng-Hao Tseng, Chi-Ming Tai, Chih-Wen Lin, Chun-Ying Wu, Jaw-Town Lin
BACKGROUND: Therapeutic duration of nucleos(t)ide analogues for chronic hepatitis B (CHB) is not indefinite in many parts of the world. Viral reactivation is common off therapy but the risk of subsequent clinical outcome remains unclear and unpredictable. AIM: We aimed to quantify the incidence of and explore the predictors for clinical flare following virological relapse in CHB patients who discontinue entecavir therapy. METHODS: This multicenter cohort study prospectively monitored 133 CHB patients who were HBeAg-negative and viral DNA-undetectable when discontinuing entecavir after at least 3 years on therapy...
January 25, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28107377/hbeag-seroconversion-in-hbeag-positive-chronic-hepatitis-b-patients-receiving-long-term-nucleos-t-ide-analog-treatment-a-systematic-review-and-network-meta-analysis
#16
Tongjing Xing, Hongtao Xu, Lin Cao, Maocong Ye
BACKGROUND: HBeAg seroconversion is an important intermediate outcome in HBeAg-positive chronic hepatitis B (CHB) patients. This study aimed to compare the effect of nucleos(t)ide analogs (NAs) on HBeAg seroconversion in treating CHB with lamivudine, adefovir, telbivudine, entecavir, and tenofovir. METHODS: Network meta-analysis of NA treatment-induced HBeAg seroconversion after 1-2 years of treatment was performed. In addition, NA treatment-induced HBeAg seroconversion after 3-5 years of treatment was systematically evaluated...
2017: PloS One
https://www.readbyqxmd.com/read/28103819/telbivudine-versus-entecavir-in-patients-with-undetectable-hepatitis-b-virus-dna-a-randomized-trial
#17
RANDOMIZED CONTROLLED TRIAL
Jihyun An, Young-Suk Lim, Gi-Ae Kim, Seong-Bong Han, Wonhee Jeong, Danbi Lee, Ju Hyun Shim, Han Chu Lee, Yung Sang Lee
BACKGROUND: Telbivudine has been suggested to induce hepatitis B surface antigen (HBsAg) decline to the similar degree as pegylated interferon. We aimed to investigate whether telbivudine could further decrease HBsAg titer in patients who maintain undetectable serum hepatitis B virus (HBV) DNA after initial entecavir treatment. METHODS: In this open-label trial, patients who had serum HBsAg and HBV DNA levels ≥1,000 IU/mL and <60 IU/mL, respectively, following entecavir (0...
January 19, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/28081589/preemptive-antiviral-therapy-with-entecavir-can-reduce-acute-deterioration-of-hepatic-function-following-transarterial-chemoembolization
#18
Sun Hong Yoo, Jeong Won Jang, Jung Hyun Kwon, Seung Min Jung, Bohyun Jang, Jong Young Choi
BACKGROUND/AIMS: Hepatic damage during transarterial chemoembolization (TACE) is a critical complication in patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Apart from its role in preventing HBV reactivation, there is some evidence for the benefits of preemptive antiviral therapy in TACE. This study evaluated the effect of preemptive antiviral therapy on acute hepatic deterioration following TACE. METHODS: This retrospective observational study included a prospectively collected cohort of 108 patients with HBV-related HCC who underwent TACE between January 2007 and January 2013...
December 2016: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/28078526/effectiveness-and-safety-of-entecavir-or-tenofovir-in-a-spanish-cohort-of-chronic-hepatitis-b-patients-validation-of-the-page-b-score-to-predict-hepatocellular-carcinoma
#19
Mar Riveiro-Barciela, David Tabernero, José L Calleja, Sabela Lens, María L Manzano, Francisco Gea Rodríguez, Javier Crespo, Belén Piqueras, Juan M Pascasio, Carmen Comas, Maria L Gutierrez, Alberto Aguirre, Emilio Suárez, Javier García-Samaniego, Miguel Rivero, Doroteo Acero, Miguel Fernandez-Bermejo, Diego Moreno, Pilar Sánchez-Pobre, Beatriz de Cuenca, J J Moreno-Palomares, Rafael Esteban, Maria Buti
BACKGROUND: Long-term antiviral therapy has resulted in viral suppression and biochemical response in chronic hepatitis B, although the risk of hepatocellular carcinoma has not been abolished. The Page-B score could be useful to estimate the probability of HCC. AIMS: To analyze the effectiveness and safety of entecavir or tenofovir for more than 4 years and the usefulness of Page-B score in the real-world setting. METHODS: Analysis of Caucasian chronic hepatitis B subjects treated with entecavir or tenofovir from the prospective, multicenter database CIBERHEP...
January 11, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28067752/efficacy-and-safety-of-lamivudine-versus-entecavir-for-treating-chronic-hepatitis-b-virus-related-acute-exacerbation-and-acute-on-chronic-liver-failure-a-systematic-review-and-meta-analysis
#20
Kuang-Wei Huang, Ka-Wai Tam, Jiing-Chyuan Luo, Yi-Chun Kuan
BACKGROUND: Oral nucleos(t)ide analogs are recommended for patients with chronic hepatitis B virus (HBV)-related acute exacerbation (AE) and acute-on-chronic liver failure (ACLF). The efficacy and safety of administering entecavir (ETV) and lamivudine (LAM) to such patients remain unclear. METHODS: A comprehensive literature search was performed to select studies published before December 2015 on therapy involving ETV or LAM for chronic HBV-related AE with or without ACLF...
August 30, 2016: Journal of Clinical Gastroenterology
keyword
keyword
2107
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"